Objective We retrospectively investigated the efficacy and predictive factors for the treatment outcomes of bortezomib plus dexamethasone (BD) as second-line induction therapy prior to high-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) in multiple myeloma (MM) patients. Methods Sixty-six transplant eligible MM patients treated by the Kyoto Clinical Hematology Study Group between 2006 and 2011 were investigated. Conventional induction chemotherapy, including vincristine, doxorubicin and dexamethasone (VAD) and high-dose dexamethasone (HDD), was used as first-line induction therapy in all patients, seven (10.6%) of whom attained a very good partial response (VGPR). Of the 59 patients who did not attain VGPR with VAD or HDD, 33 were given BD as second-line induction therapy prior to HDT/ASCT. Results Patients not treated with BD induction showed an overall response rate (ORR, i.e., better than partial response) of 85.3% after induction therapy, while the ORR of patients treated with BD induction improved from 42.4% after conventional induction therapy to 84.8% after BD. The overall survival (OS) and progression-free survival (PFS) of patients not treated with BD induction were not significantly influenced by the response to induction therapy. Among the patients treated with BD, failure in attaining VGPR prior to ASCT was associated with a significantly shorter PFS and it also tended to show a shorter OS, while the disease stage and achievement of a complete response after HDT/ASCT had no impact on OS or PFS. Conclusion The achievement of at least VGPR with second-line BD induction therapy is a prerequisite for attaining longer OS and PFS after HDT/ASCT.
Introduction
High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) is considered to be the standard treatment for young patients with symptomatic multiple myeloma (MM) (1, 2) . Although some reports have previously demonstrated that the attainment of a complete response (CR) or at least a very good partial response (VGPR) following HDT/ASCT is a prerequisite for achieving favorable long-term outcomes following HDT/ASCT therapy, this concept is controversial (3) (4) (5) (6) (7) (8) . Before the arrival of novel anti-MM agents, conventional cytotoxic chemotherapies such as high-dose dexamethasone (DEX and HDD, respectively) and vincristine, doxorubicin and DEX (VAD) were utilized as standard induction regimens prior to HDT/ ASCT. Although these chemotherapies are capable of reducing the tumor burden and resolving symptoms due to myeloma-related organ or tissue impairment, the rate of achieving better than a VGPR is at most 20% and that of a CR is less than 10% before HDT/ASCT. Novel anti-MM agents such as bortezomib (BTZ) and immunomodulatory drugs (IMiDs) have recently greatly improved the treatment responses as well as the long-term outcomes of patients with MM. Indeed, combination chemotherapies involving BTZ and thalidomide (THAL) have proven to be powerful inducers of higher CR and VGPR rates and thus generate longer progression-free survival (PFS) and overall survival (OS) periods in transplantation-ineligible MM patients (9, 10) . In addition, these novel agents have been found to contribute to higher response rates when used for induction therapy prior to HDT/ASCT, although it remains unclear whether the higher response rates resulting from induction therapy using novel agents such as BTZ and THAL contribute to longer survival (11, 12) . Furthermore, it remains to be verified whether the degree of response to induction therapy achieved with novel agents is relevant for post-ASCT longterm survival.
For this study, which was conducted by the Kyoto Clinical Hematology Study Group (KOTOSG) consisting of seven independent institutes, 66 patients with newly diagnosed symptomatic MM were treated with HDT/ASCT between 2006 and 2011. BTZ, which was approved as a salvage therapeutic for MM in Japan in 2006, plus DEX (BD) was used as second-line induction therapy at the discretion of the doctors in charge in cases in which first-line conventional chemotherapy failed to attain a VGPR. In this report, we retrospectively examined the therapeutic roles of BD as second-line induction therapy before HDT/ASCT for MM.
Materials and Methods

Patients and institutes
We retrospectively analyzed 66 newly diagnosed symptomatic MM patients who underwent HDT/ASCT between 2006 and 2011 at seven independent institutes, i. 
Treatment schedule
VAD and/or HDD were administered as first-line induction therapy in all patients, except for one who received CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) therapy. The addition of BD was allowed at the doctors' discretion as second-line induction in 33 patients who had failed to attain a VGPR with the first-line treatment prior to undergoing HDT/ASCT. All patients received high-dose melphalan as the conditioning regimen for ASCT administered intravenously on days -3 and -2 (100 mg/m 2 ×2 days). The BD therapy comprised four 3-week cycles of BTZ (1.3 mg/m 2 /day) administered intravenously on days 1, 4, 8 and 11 and DEX (median, 20 mg/day) administered on days 1, 2, 4, 5, 8, 9, 11 and 12. For three patients, the DEX dose was reduced to 4-16 mg/day due to toxicity, and for two patients, BTZ was administered weekly on days 1, 8, 15 and 22 due to adverse effects (AEs) caused by the first-line induction, including peripheral neuropathy (PN) and subileus. Dose modification of BTZ was generally performed in cases of grade 1-2 AE with pain and grade 3 PN or any other grade ! 3 AE related to BTZ. As a result, eleven (33.3%) of the patients treated with BD had to have the dose of BTZ reduced to either 1.0 mg/m 2 or 0.7 mg/m 2 due to the occurrence of AEs during the second-line induction. The resultant median number of BD cycles was three (range, 1-7 cycles). Post-transplantation therapy was not indicated and it was only performed in individual cases based on the patient's clinical history.
Response criteria
The International Myeloma Working Group (IMWG) criteria were used for the assessment of treatment response (13) . The disease stage was assessed according to the international staging system (ISS) (14) . PFS was defined as the period from the date of ASCT initiation to the date of the first assessment of disease progression (the initiation of maintenance treatment was considered to indicate progression in this study) or the date of death in patients who did not exhibit disease progression. OS was calculated from the date of ASCT initiation to the last date of patient follow-up or the date of death from any cause. AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
Statistical analysis
Comparisons of post-induction and post-transplant response rates, comprising CR and at least VGPR rates, in patients who received BD before transplantation and those who did not were performed using the χ 2 test. OS and PFS were estimated using the Kaplan-Meier method. The confidence interval was 95% for all analyses and p<0.05 was considered to be statistically significant. The statistical analyses were performed using the SPSS statistical software program (version 19; IBM, Armonk, NY, USA).
Results
Patient backgrounds
The median age of the 66 patients was 58 years (range, 33-68). Of the 65 patients evaluable for staging, 24 (36.4%) were classified as stage I, 22 (33.3%) were classified as stage II and 19 (28.8%) were classified as stage III according to the ISS. Of the 44 patients evaluable for chromosomal disorders, deletion of 13q (13q-) was detected using fluorescence in situ hybridization (FISH) analyses in 19 (43.2%) patients, deletion of 17p (17p-) was detected in two of 38 (5.3%) patients, t(4;14) was detected in 11 of 48 (22.9%) patients and t(14;16) was detected in one of 35 (2.9%) patients (Table 1) .
Response to induction therapy and HDT/ASCT
The overall response to induction therapy and HDT/ ASCT is summarized in Table 2 . Following the first-line induction therapy, 33 patients (50.0%) received BD as secondline induction therapy prior to undergoing HDT/ASCT (BD (+)) and 33 did not (BD(-)) ( Table 2) . No significant differences were identified in ISS stage or the frequency of highrisk cytogenetics between the BD(+) and BD(-) groups (Table 1). Eighteen of the BD(+) patients received VAD, 14 received HDD and one received CHOP as first-line induction therapy prior to BD. The overall response rate (ORR) of first-line therapy in the BD(+) cohort was 42.4% without any cases of VGPR or CR. Among 33 patients, VAD was administered in 30 of the BD(-) patients, HDD was administered in five patients and cyclophosphamide plus VAD (CVAD) and melphalan plus prednisolone (MP) were each administered in one patient. The ORR for first-line induction therapy was 85.3% in the BD(-) cohort, including better than a VGPR in 21.2% of the patients. In the BD(+) cohort, the addition of BD induced a CR in two patients, a VGPR in 11 patients and a PR in 15 patients, meaning that the addition of BD resulted in an improvement in the ORR from 42.4% to 84.8% and induced better than a VGPR in 39.4% (compared to 0%) of the patients prior to HDT/ASCT. In addition, the post-transplantation CR rate tended to be higher in the BD(+) group than in the BD(-) group (30.3% vs. 12.1%, p=0.071), while the rates of both VGPR or better (57.6% vs. 45.4%, p=0.324) and ORR (90.9% vs. 87.8%, p=0.955) were similar between the two cohorts ( Table 2 ).
Long-term treatment outcomes
In the BD(+) cohort, with a median follow-up of 451 days, the median OS has not yet been reached, while the 3-year OS was 57.9% (Fig. 1a) , the median PFS was 619 days and the 3-year PFS was 36.8% (Fig. 1b) . The impact of the treatment response prior to HDT/ASCT was also investigated (Fig. 1c, d ). While patients who attained a VGPR or better with BD before undergoing ASCT tended to exhibit longer OS than the patients who did not (median OS: not reached vs. 878 days, p=0.286), the PFS of the patients who attained better than a VGPR with BD before undergoing ASCT was significantly longer than that of the patients who failed to attain a VGPR (median PFS: not reached vs. 385 days, p=0.038). The median follow-up period in the BD(-) cohort was 1,097 days. In this cohort, too, the median OS has not yet been reached; however, the 3-year OS was 88.1% (Fig. 2a) , the median PFS was 731 days and the 3-year PFS was 28.8% (Fig. 2b) . In contrast to that observed in the BD(+) cohort, neither OS nor PFS exhibited significant differences in terms of the response to induction therapy prior to HDT/ASCT in the BD(-) cohort (median OS: (Fig. 2c, d ). In addition, there were no significant differences in either OS or PFS in terms of the initial disease stage, the response after HDT/ ASCT or the presence or absence of the investigated poor cytogenetic abnormalities such as 13q-and t(4;14) (Table 3) .
Safety
Safety was evaluable in 54 patients (BD(+): 32, BD(-): 22). Grade 3-4 nonhematological and hematological AEs were detected in 10 patients in the BD(-) cohort (45.5%) and 15 patients in the BD(+) cohort (46.9%), with no significant differences between the two groups. The major AEs of the BD(-) group were neutropenia (31.8%), anemia (22.7%), infection (13.6%) and peripheral neuropathy (PN) (13.6%), while cardiac infarction occurred in one patient. The most frequent toxicities in the BD(+) cohort were PN (65.6%), thrombocytopenia (25.0%) and anemia (15.6%). PN occurred more frequently in the BD(+) group than in the BD(-) group (p<0.05). Seventeen patients (53.1%) developed grade 1-2 PN and four patients (12.5%) developed grade 3 PN in the BD(+) cohort, whereas only three patients (13.6%) developed grade 1-2 PN in the BD(-) cohort. PN was the most common AE requiring BTZ dose reduction.
Discussion
HDT/ASCT results in survival benefits for transplanteligible younger MM patients. Before the introduction of novel anti-MM agents, induction therapy with conventional cytotoxic agents was performed with the aim of reducing tumor burden prior to HDT/ASCT. However, the therapeutic significance of response to such induction therapy for the long-term outcome following HDT/ASCT has remained controversial. Indeed, the long-term outcome for transplanteligible MM patients who were less sensitive to induction therapies with conventional cytotoxic agents was not inferior to that for patients who were sensitive (15, 16) . This was also the case in our study, which showed that the response to induction therapy had no impact on either OS or PFS of the BD(-) cohort. Moreover, the attainment of VGPR following HDT/ASCT remained the only widely accepted predictor for better long-term outcome for HDT/ASCT before the introduction of novel anti-MM agents (6) .
Recent reports have demonstrated that the use of novel anti-MM agents such as BTZ or IMiDs may yield substantial therapeutic benefits as the induction prior to transplantation (11, 12, (17) (18) (19) (20) (21) (22) . The use of BTZ has the potential to enhance CR and VGPR rates before ASCT, and has therefore been expected to have a favorable impact on overall prognosis. Despite this anticipation, however, the long-term benefits of the incorporation of BTZ into induction therapy have been controversial (11, 12, (23) (24) (25) . In Japan, the use of BTZ was approved only as a salvage therapeutic option, but not as the first-line treatment, for MM until 2011, so during this time BTZ was used for transplant-eligible patients mostly as the second-line induction at the discretion of the doctor in charge, in our cases. This situation provided us with an opportunity to investigate (i) how BTZ was actually utilized when its use was allowed only for patients those did not attain VGPR by means of conventional cytotoxic agents, and (ii) the impact of the degree of response to second-line BD on the long-term outcome following HDT/ASCT. Under these circumstances, 59 of 66 patients did not attain VGPR with the aid of conventional cytotoxic agents, and 33 of the 59 were shifted to salvage treatment with BD at their doctor's discretion. It should be noted that the BD(+) cohort contained significantly more patients who did not attain partial response (PR) with conventional chemotherapy (less than stable disease: BD(+) vs. BD(-), 57.6% vs. 12.1%; p< 0.01). This result seems to imply that, from 2006 to 2011, doctors belonging to the KOTOSG tended to shift patients who were comparatively more refractory to conventional chemotherapy to salvage BD treatment in their daily practice. Similar to the findings of previous studies, the secondline BD induction chemotherapy, compared with VAD or HDD induction, improved ORR before HDT/ASCT and CR following ASCT. More importantly, patients who attained better than VGPR as a result of the addition of BD before ASCT, showed significantly longer PFS than patients who could not attain VGPR even with BD. OS also tended to be longer for patients who attained VGPR or better with BD compared with patients who could not attain VGPR even with BD without a significant difference, although the median observation period was only 451 days. These results suggest that the attainment of at least VGPR prior to HDT/ ASCT may be a prerequisite for obtaining the survival benefits associated with BTZ-containing induction. In other words, failure to attain VGPR with BD may be due to strong drug resistance of individual MM patients even when high-dose melphalan therapy is used. Although patients treated with BD before HDT/ASCT did not show the same survival benefits as did the patients treated without BD in our series, this does not negate the use of BTZ for induction therapy. One of the most likely explanations for the less than satisfactory long-term results for the BD(+) cohort is that the overall chemoresponsiveness of the BD(+) cohort in our study was inferior to that of the BD(-) cohort. Indeed, the response rates to VAD or HDD of the BD(-) cohort seem comparable to those reported by previous studies (26, 27) , while the patients in the BD(+) cohort showed poorer treatment response to the first-line induction therapies with cytotoxic agents. Another explanation is that the prognosis of the patients who were refractory to BD was extremely poorer than other cohorts, which impaired the overall long-term outcomes of BD(+) cohort in total. Our study suggests an important insight, namely, the change in the clinical significance of pre-ASCT response between in the era of conventional cytotoxic agents and that in the era of BTZ. Before the era of BTZ, the degree of response to induction therapy showed no impact on the long-term outcome following ASCT, and the post-ASCT response was the critical factor which predicted the long-term outcome. In contrast, in the era of BTZ, the degree of response to induction therapy with BTZ now predicts the post-ASCT outcome. In other words, our study suggested the possibility that poor response to BTZ could not be overcome even with HDT with high-dose melphalan.
As for the induction therapy, we now do not consider BD to be the best among the various induction regimens incorporating BTZ. Although a direct comparison of the therapeutic efficacies of BD and conventional chemotherapies for the BD(+) and BD(-) cohorts was not feasible due to patient bias, BD is unlikely to constitute a promising therapy for overcoming resistance to conventional cytotoxic agents or for generating highly favorable long-term outcomes. For this reason, the more intensive BTZ-containing induction regimens, such as BD plus THAL, plus doxorubicin, or plus cyclophosphamide, for the first-line induction can be expected to induce higher rates of better than VGPR and to produce better long-term outcomes (18, 28, 29) . In addition, BD induction, in comparison with VAD, has been shown to have a significantly beneficial effect on PFS, especially for patients with poor-risk cytogenetics compared with VAD (17) . Cytogenetic abnormalities detected by FISH analysis in our se- Table 3 . Analysis of Prognostic Factors Predicting for OS and PFS after HDT/ASCT BD: bortezomib plus dexamethasone, OS: overall survival, PFS: progression-free survival, VGPR: very good partial response, CR: complete response, HDT/ASCT: high dose therapy supported by autologous stem cell transplantation, ISS: international staging system, NS: not statistically significant, S: significant ries did not significantly affect treatment outcome (data not shown), which is comparable with our previously reported finding that cytogenetic abnormalities detected by FISH were not associated with poorer outcomes for patients treated with BD (30). It should also be noted that there was a significantly higher incidence of PN in the BD(+) cohort than in the BD(-) cohort, as also reported previously (31). PN was the most intractable AE and required reduction of the BTZ dosage and sometimes even discontinuation of BD. A more beneficial strategy for the use of BTZ is thus also needed for preventing PN and maintaining a better quality of life when triplet induction containing BTZ is used.
In conclusion, our results suggest that attainment of better than VGPR before HDT/ASCT as a result of the addition of BD as the second-line induction may have a positive prognostic impact for MM patients who attained only PR after conventional induction chemotherapies. On the other hand, failure to attain VGPR with BD appears to be a powerful predictor for poorer PFS after HDT/ASCT and perhaps for OS as well. Poor response to the second-line BD identified patients who were insensitive to both conventional cytotoxic agents and BTZ in this study, and such patients were not sufficiently rescued even with HDT/ASCT. New therapeutic strategy should be explored for such patients. Although BD induces higher ORR prior to HDT/ASCT, our findings reflect the controversial opinions regarding the long-term efficacy of BD for induction prior to HDT/ASCT for MM, especially when used as the second-line induction therapy.
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